Gastrin Vaccine Alone and in Combination With an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer
Gastric cancer is a leading cause of cancer-related deaths worldwide. Recently, clinical studies have demonstrated that many of those with advanced gastric cancer are responsive to immune checkpoint antibody therapy, although the median survival even with these new agents is less than 12 months for...
Enregistré dans:
Auteurs principaux: | Jill P. Smith, Hong Cao, Wenqiang Chen, Kanwal Mahmood, Teresa Phillips, Lynda Sutton, Allen Cato |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3a3572a1ffa44036b51f169e5df25342 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer
par: Wang Z, et autres
Publié: (2021) -
Establishment of a Prognostic Signature of Stromal/Immune-Related Genes for Gastric Adenocarcinoma Based on ESTIMATE Algorithm
par: Shan Yu, et autres
Publié: (2021) -
The Burden of Peritoneal Metastases from Gastric Cancer: A Systematic Review on the Incidence, Risk Factors and Survival
par: Anouk Rijken, et autres
Publié: (2021) -
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
par: Alberto Bongiovanni, et autres
Publié: (2021) -
Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
par: Cor J. Ravensbergen, et autres
Publié: (2021)